Emma Pearce

1.1k total citations · 1 hit paper
10 papers, 770 citations indexed

About

Emma Pearce is a scholar working on Epidemiology, Public Health, Environmental and Occupational Health and Microbiology. According to data from OpenAlex, Emma Pearce has authored 10 papers receiving a total of 770 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 3 papers in Public Health, Environmental and Occupational Health and 3 papers in Microbiology. Recurrent topics in Emma Pearce's work include Pneumonia and Respiratory Infections (7 papers), Respiratory viral infections research (5 papers) and Pneumocystis jirovecii pneumonia detection and treatment (3 papers). Emma Pearce is often cited by papers focused on Pneumonia and Respiratory Infections (7 papers), Respiratory viral infections research (5 papers) and Pneumocystis jirovecii pneumonia detection and treatment (3 papers). Emma Pearce collaborates with scholars based in United Kingdom, United States and Netherlands. Emma Pearce's co-authors include Alan Sher, P Natovitz, Patrícia Scott, David Goldblatt, Elizabeth Miller, Nick Andrews, Lucy Roalfe, Polly Burbidge, Shamez Ladhani and Pauline A. Waight and has published in prestigious journals such as The Journal of Immunology, The Lancet Infectious Diseases and Vaccine.

In The Last Decade

Emma Pearce

10 papers receiving 763 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study

2014 393 citations Nick Andrews, Pauline A. Waight et al. The Lancet Infectious Diseases profile →

Peers

Emma Pearce

EPIDE

PHEOH

IMMUN

MICRO

PARAS

Gretchen Cooley United States

J. Leeuwenburg Netherlands

Barrie R. Jones United Kingdom

Judith B. Weiss United States

Monika Berney Switzerland

Pateh Makalo Gambia

Morgan M. Goheen United States

Аlevtina M. Savicheva Russia

Olivia Peuchant France

Waldely O. Dias Brazil

Gretchen Cooley United States

Emma Pearce

477 ×0.8

EPIDE

387 ×1.2

PHEOH

43 ×0.3

IMMUN

90 ×0.6

MICRO

146 ×1.7

PARAS

Citations per year, relative to Emma Pearce Emma Pearce (= 1×) peers Gretchen Cooley

Countries citing papers authored by Emma Pearce

Since Specialization

Citations

This map shows the geographic impact of Emma Pearce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Pearce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Pearce more than expected).

Fields of papers citing papers by Emma Pearce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emma Pearce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Pearce. The network helps show where Emma Pearce may publish in the future.

Co-authorship network of co-authors of Emma Pearce

This figure shows the co-authorship network connecting the top 25 collaborators of Emma Pearce. A scholar is included among the top collaborators of Emma Pearce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emma Pearce. Emma Pearce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Kawade, Anand, Emma Pearce, Lucy Roalfe, et al.. (2023). Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (SynflorixTM and Prevenar13TM)) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-labelled randomized controlled trial in Indian children. Vaccine. 41(19). 3066–3079. 9 indexed citations

Goldblatt, David, Nick Andrews, Carmen Sheppard, et al.. (2023). Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants. Vaccine. 41(19). 3019–3023. 7 indexed citations

Gallagher, Katherine E., Ifedayo Adetifa, Christian Bottomley, et al.. (2023). Population immunity to pneumococcal serotypes in Kilifi, Kenya, before and 6 years after the introduction of PCV10 with a catch-up campaign: an observational study of cross-sectional serosurveys. The Lancet Infectious Diseases. 23(11). 1291–1301. 3 indexed citations

Swarthout, Todd D., Marc Henrion, Deus Thindwa, et al.. (2022). Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study. The Lancet Infectious Diseases. 22(12). 1737–1747. 24 indexed citations

Jones, Scott, Lucy Roalfe, Suzanne Byrne, et al.. (2019). Assignment of Serotype-Specific IgG1, IgG2, and IgA Weight-Based Antibody Units to the Human Pneumococcal Standard Reference Serum, 007sp. mSphere. 4(3). 2 indexed citations

Andrews, Nick, Pauline A. Waight, Polly Burbidge, et al.. (2014). Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. The Lancet Infectious Diseases. 14(9). 839–846. 393 indexed citations breakdown →

Ladhani, Shamez, Nick Andrews, Pauline Waight, et al.. (2014). Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule. Vaccine. 33(5). 648–655. 11 indexed citations

Scott, Phillip, Emma Pearce, P Natovitz, & Alan Sher. (1987). Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract.. The Journal of Immunology. 139(9). 3118–3125. 89 indexed citations

Scott, Patrícia, Emma Pearce, P Natovitz, & Alan Sher. (1987). Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.. The Journal of Immunology. 139(1). 221–227. 196 indexed citations

10.

Sher, Alan, Emma Pearce, Sara Hieny, & Stephanie L. James. (1986). Induction of protective immunity against Schistosoma mansoni by a nonliving vaccine. IV. Fractionation and antigenic properties of a soluble adult worm immunoprophylactic activity.. The Journal of Immunology. 136(10). 3878–3883. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact